Cat. No. 1047
No more than 1 g per customer per year to be sold.
Chemical Name: 7α,17β-[9-[(4,4,5,5,5-Pentafluoropent
Biological ActivityA high affinity estrogen receptor antagonist (IC50 = 0.29 nM), devoid of any partial agonism both in vitro and in vivo. Also high affinity agonist at the membrane estrogen receptor GPR30.
Licensing InformationSold with the permission of AstraZeneca UK Ltd.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Wakeling et al (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res. 51 3867. PMID: 1855205.
de Cupis et al (1995) Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol and IGF-I induced proliferation of human breast cancer-derived cells. Br.J.Pharmacol. 116 2391. PMID: 8581274.
Howell et al (2000) ICI 182,780 (FaslodexTM): Development of a novel, "pure" antiestrogen. Cancer 89 817. PMID: 10951345.
Thomas et al (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 146 624. PMID: 15539556.
If you know of a relevant citation for this product please let us know.
Keywords: ICI 182,780, supplier, High, affinity, GPR30, agonist, Estrogen, receptors, antagonists, ER, ERR, ICI182780, AstraZeneca, GPER